Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed relapsed or refractory HIV-associated non-Hodgkin lymphoma (NHL) * Must have histologic or cytologic documentation of prior AIDS-associated NHL (i.e., at time of diagnosis) for clinically relapsed and/or refractory disease for which biopsy is not feasible * Must have documented HIV seropositivity * Must have documentation of Epstein-Barr Virus (EBV)- and/or human herpes virus-8 (HHV-8)- positive infection within the lymphoma (i.e., LMP-1, LANA expression, or positive Epstein-Barr-encoded RNAs \[EBERs\]) PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100% * Life expectancy \> 2 months * ANC ≥ 1,000/mm³\* (growth factor support allowed) * Hemoglobin ≥ 8.0 g/dL\* (growth factor support allowed) * Platelet count ≥ 100,000/mm³ * Total bilirubin ≤ 1.5 mg/dL * AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN) * Serum creatinine ≤ ULN * Creatinine clearance ≥ 50 mL/min * Negative pregnancy test * Not pregnant or nursing * Fertile patients must use effective contraception NOTE: \*Patients with lymphomatous involvement of the bone unable to meet hematologic criteria are allowed Exclusion criteria: * Peripheral neuropathy ≥ grade 2 * Uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection * Opportunistic infections controlled by antimicrobial or suppressive therapy allowed, u…